Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab Autoinjector in Moderate-to-Severe Atopic Dermatitis
NCT05194540Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tralokinumab in atopic dermatitis (AD), sponsored by LEO Pharma. Started Jan 2022; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05194540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194540.